SCHEDULE: Bank of America Discloses 15% Stake in Aptevo Therapeutics
Beneficial Ownership Disclosure
Bank of America Corporation has disclosed a 15.0% beneficial ownership stake in Aptevo Therapeutics Inc. common stock.
Summary
- Bank of America Corporation /DE/ has filed a Schedule 13G, reporting beneficial ownership of 494,341 shares of Aptevo Therapeutics Inc. common stock.
- This ownership represents 15.0% of Aptevo Therapeutics Inc.'s outstanding common stock.
- The percentage is calculated based on 3,287,918 outstanding shares, as referenced in Aptevo Therapeutics Inc.'s Form 10-Q filed on August 11, 2025.
- Bank of America Corporation, a parent holding company, is filing on behalf of its wholly-owned subsidiaries, BofA Securities, Inc. (a broker-dealer) and Bank of America N.A. (a bank).
- The reporting persons hold shared voting power and shared dispositive power over all 494,341 beneficially owned shares.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a significant institutional ownership stake. While neutral in its presentation, a 15% stake by a major financial institution could be perceived as a moderately positive signal by the market regarding the issuer's prospects.
Positives
- Bank of America Corporation's significant 15.0% beneficial ownership stake in Aptevo Therapeutics Inc. may be interpreted by the market as a vote of confidence in the company's prospects.
Negatives
- No negative operational or financial information regarding Aptevo Therapeutics Inc. is disclosed in this beneficial ownership filing.
Risks
- No specific risks related to Aptevo Therapeutics Inc.'s operations or financial health are disclosed in this beneficial ownership filing.
Future Outlook
NA
Industry Context
This filing is a disclosure of beneficial ownership by a financial institution in a biotechnology company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders may view the significant institutional ownership by Bank of America Corporation as a positive indicator of investor confidence in Aptevo Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-08-11 | Date of Form 10-Q filing by Aptevo Therapeutics Inc., referencing 3,287,918 outstanding shares used for percentage calculation. |
| 2025-09-30 | Date of event which required the filing of this statement (beneficial ownership threshold met). |
| 2025-10-06 | Date the Schedule 13G was signed by Bank of America Corp /DE/. |
Keywords
Aptevo Therapeutics, Bank of America, Schedule 13G, beneficial ownership, common stock, institutional ownership, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.